Blog

CAR-T growing up with big pharma’s big bet – BioPharma Dive

CART growing up with big pharma's big bet
BioPharma Dive
In the span of just five months, Gilead Sciences Inc. and Celgene Corp. — both large-cap biotechs with long-term growth worries — each made major bets on the potential of cancer cell therapies. With two of the three largest biotech deals in the last

2018-02-20 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.